Methylene Blue

Abstract

Methylene blue (MB) has received much attention in the perioperative and critical care literature because of its ability to antagonize the profound vasodilation seen in distributive (also referred to as vasodilatory or vasoplegic) shock states. This review will discuss the pharmacologic properties of MB and review the critical care, liver transplantation, and cardiac anesthesia literature with respect to the efficacy and safety of MB for the treatment of shock. Although improved blood pressure has consistently been demonstrated with the use of MB in small trials and case reports, better oxygen delivery or decreased mortality with MB use has not been demonstrated. Large randomized controlled trials are still necessary to identify the role of MB in hemodynamic resuscitation of the critically ill.

CelloMOF: Nanocellulose Enabled 3D Printing of Metal–Organic Frameworks

“…The curcumin drug release from the 3D printed Curcumin‐ZIF‐8@TOCNF (denoted CelloZIF8‐Cur) scaffolds has been investigated. The processing and controlled release are also demonstrated using methylene blue, a therapeutic agent used for treatment of methemoglobinemia, Vasoplegia, and neurodegenerative diseases and cancers, as a guest molecule in 3D printed Cello‐ZIF8.…”

Targeting mitochondrial dysfunction in CNS injury using Methylene Blue; still a magic bullet?

“…He noted that MB was selectively taken up by the nervous tissue, and the term “magic bullet” was coined by this phenomenon. Since then, MB has been used in humans safely for over 120 years to treat variety of diseases, including methemoglobinemia, urinary tract infection, nitric oxide-induced hypotensive complications from septic shock, cardiopulmonary bypass, and in diagnostic procedures and Vasoplegic syndrome [53–55] [56–59]. It is also an antidote to cyanide and carbon monoxide poisoning [60], and shows neuroprotective property for stroke, Parkinson’s disease, Alzheimer’s disease, and optic neuropathy [61–64].…”

New member to join the family of vasopressors in septic shock: methylene blue (dual case report)

“…Distribütif şokun bir parçası olan bu patoloji, sepsis, anaflaksi, adrenal yetmezlik, ilaca bağlı şok ve postkardiopulmoner baypas vazoplejisi gibi birçok etiyolojiye sahiptir [1] . Tedavi genellikle altta yatan nedenin belirlenip, intravenöz sıvılar ve vazoaktif ajanlarla destekleyici bakımın sağlanmasına yöneliktir [2] . Konvansiyonel tedavilere ek olarak, vazodilatasyon ve doku hipoperfüzyonunu önlemek için hücresel yolların NO ve cGMP düzeyinde inhibe edilmesi üzerine araştırmalar yapılmıştır [2] .…”

“…Tedavi genellikle altta yatan nedenin belirlenip, intravenöz sıvılar ve vazoaktif ajanlarla destekleyici bakımın sağlanmasına yöneliktir [2] . Konvansiyonel tedavilere ek olarak, vazodilatasyon ve doku hipoperfüzyonunu önlemek için hücresel yolların NO ve cGMP düzeyinde inhibe edilmesi üzerine araştırmalar yapılmıştır [2] . Refrakter vazodilatatör şok için; bir guanilil siklaz inhibitörü olan ve cGMP üretimini inhibe eden metilen mavisi kullanılabilir.…”